Publicis' CEO dismisses Meta threat, raises yearly growth guidance
(Reuters) -French advertising firm Publicis on Thursday raised its full-year organic growth forecast following stronger-than-expected second-quarter results, as CEO Arthur Sadoun dismissed concerns over Meta's AI-powered ad creation system.
"When Meta comes along and says that they can do everything themselves, I think that they are completely underestimating the intelligence of our customers, who, moreover, are not fooled," he said during an earnings call.
Sadoun highlighted clients' reluctance to entrust their data to single platforms.
"None of our customers want to leave their data in the world of 'walled gardens.' None of our customers want to work with a single platform," he said, adding that customers wanted to measure the impact of their spending "which obviously cannot be offered by those that do it within their own walls."
Publicis said it has completed its $12 billion, decade-long tech transformation and will now focus on executing its strategy. The company highlighted its proprietary platform, which leverages in-house AI and big data capabilities to track consumer behavior and target individualized ads for over 4 billion internet users globally.
"I've been hearing for nine years that the platforms are going to 'eat us for breakfast.' Honestly, I think it's time to stop talking about how platforms are going to replace us, because it's not a reality," Sadoun stressed.
The company upgraded its 2025 organic growth forecast to close to 5%, up from the previous range of 4% to 5%, after reporting 5.9% net revenue organic growth in the second quarter. Publicis cited a "unprecedented new business run" in the first half of 2025, including wins with Coca-Cola, Nespresso, Lego, Paramount, and Spotify.
Second-quarter revenue rose 10%, with growth across all regions: 5.3% in the U.S., 4.6% in Europe and 5.7% in Asia-Pacific. The company reported $5.2 billion in net new business wins for the first half of 2025, outpacing flatlining competitors such as WPP, Omnicom, Dentsu, and Interpublic, according to JPMorgan data.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Obagi, Milk Makeup Owner Waldencast Enters Filler Market With New Acquisition
Obagi injectables are in the works. Waldencast, the parent company of Milk Makeup and Obagi Medical skin care, has acquired Novaestiq Corp., an aesthetic and medical dermatological innovations company, as well as the U.S. rights to the Saypha line of hyaluronic acid injectable gels. Terms of the deal were not disclosed. More from WWD Polite Society Achieves in Two Years What Took Too Faced a Decade Ariana Grande's R.e.m. Beauty Hires CEO Lux Pascal, Vanessa Kirby and Xochitl Gomez Lead '60s-inspired Beauty Trend at 'The Fantastic Four: First Steps' Premiere The acquisition will sit under the Obagi brand, which will expand its offerings beyond skin care into the U.S. dermal filler market. 'We are excited to further diversify Obagi Medical's portfolio of medical-grade skin care with consumer centric, in-office injectable procedures,' said Michel Brousset, cofounder and chief executive officer of Waldencast. 'Adding proven products into our portfolio increases our addressable market and allows us to deliver solutions for professionals and patients seeking both skin care and aesthetic treatments, all under the trusted Obagi Medical brand.' Saypha, a product of Croma-Pharma GmbH, is developed and manufactured in Austria and marketed in more than 80 countries, but not yet available in the U.S. It is currently undergoing U.S. Food and Drug Administration approval. According to Waldencast, Saypha's proprietary technology delivers advanced HA treatments through a stable 3D matrix designed to provide natural-looking results with optimally balanced gel characteristics. 'We believe that great results start with great skin care and are perfected with great after care,' said Dr. Suzan Obagi, chief medical director at Obagi Medical. 'By combining Obagi Medical skin care with injectable procedures under the guidance of a qualified professional, patients can achieve more significant, longer-lasting and natural-looking results. This acquisition also allows our professionals to offer patients more personalized, higher quality and safer products that their customers are looking for.' On putting it under the Obagi brand as opposed to running it as a standalone entity, Brousset said: 'The Obagi brand is actually a big part of what is going to boost the performance of this business. Our vision is to create Obagi as a mega brand in the world of beauty aesthetics, and have Obagi as the big platform to market [aesthetics] through the trust that physicians have on Obagi and through the trust that consumers have on our existing infrastructure system business model.' Brousset is open to more M&A opportunities, especially in the aesthetics space. 'This is our first step into aesthetics. We expect to have more steps in the future.' Best of WWD Sesame Oil Skin Care: The Secret to Hydrated Skin or a Recipe for Clogged Pores? How Grooming Is Introducing Men to Self-care and Redefining Masculinity Clean Beauty Brand Ignae Makes Big U.S. Push With a New Look Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
25 minutes ago
- Yahoo
JPMorgan Warns of Stocks Complacency as Earnings Outlook Dims
(Bloomberg) -- Signs of stock-market complacency are emerging as the searing equities rally coincides with an acceleration in earnings downgrades, according to JPMorgan Chase & Co. quantitative strategists. Trump Awards $1.26 Billion Contract to Build Biggest Immigrant Detention Center in US Why the Federal Reserve's Building Renovation Costs $2.5 Billion Salt Lake City Turns Winter Olympic Bid Into Statewide Bond Boom Milan Corruption Probe Casts Shadow Over Property Boom How San Jose's Mayor Is Working to Build an AI Capital Stocks have bounced back from April's slump at an even faster pace than after the Covid pandemic, sending the MSCI World Index and many regional benchmarks to record highs. At the same time, consensus data shows downgrades outpacing upgrades sharply in global earnings revisions, the JPMorgan team led by Khuram Chaudhry said. 'There appears to be an environment of bullish sentiment, speculation, and a growing air of complacency,' they wrote. 'Either sell-side analysts are about to start a new round of upward revisions or the market is at risk of suffering a period of increased volatility and draw-downs. Something has to give!' Net revisions for global earnings have slid 14.3% on a one-month basis and 18.7% over three months. For now, the US shows fewer cuts, thanks to strength in sectors like technology, they said, while regions like Asia and Europe face accelerating earnings-per share downgrades. Guidance in Europe has been weak, given the uncertainty around tariffs, with a slew of profit warnings, especially in the chemical sector. In the US, expectations are high for the Big Tech names after a 35% surge in the Nasdaq 100 since its April low. Cracks could still emerge in the second half, the analysts said. 'The US market is thriving on sectors like Technology and the 'Magnificent 7' stocks, fueled by the Generative AI trend,' they wrote. 'Yet cracks and volatility are increasingly likely in the second half. Investors should be on the lookout for a potential market rotation!' UK Profit Warnings Citing Geopolitics Hit a Record High, EY Says For those expecting looser monetary policy to boost the market, the three to four cuts priced in over the coming 12 months shouldn't be taken as a positive, Chaudhry and his team said. 'Any forthcoming interest rate cuts may signal underlying weakness, rather than a build up in positive sentiment.' Elon Musk's Empire Is Creaking Under the Strain of Elon Musk Burning Man Is Burning Through Cash A Rebel Army Is Building a Rare-Earth Empire on China's Border Thailand's Changing Cannabis Rules Leave Farmers in a Tough Spot How Starbucks' CEO Plans to Tame the Rush-Hour Free-for-All ©2025 Bloomberg L.P.
Yahoo
25 minutes ago
- Yahoo
CME's second-quarter profit rises on higher trading activity
(Reuters) -Derivatives exchange CME Group reported a higher second-quarter profit on Wednesday, as record volatility boosted demand for its products, which are often used to hedge against macroeconomic uncertainty. Profit attributable to CME shareholders was $1.01 billion, or $2.81 per share, for the three months ended June 30, compared with $872 million, or $2.42 per share, reported last year.
